SyB L-1701/L-1702
SyB L-1701: RTD liquid / SyB L-1702: RI administration (generic name: bendamustine hydrochloride hydrate, product name: TREAKISYM
overview
Bendamustine hydrochloride (generic name) is an anti-cancer drug that has been used for many years in Germany as a treatment for non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia (product name: Ribomustine®). There are no excellent drugs in this field, and for patients with relapsed/refractory low-grade non-Hodgkin's lymphoma and mantle cell lymphoma, this drug is a drug that targets Underserved Therapeutic Areas, which is exactly what our group's corporate mission is, and that was the deciding factor for introducing it. In Japan, it has been approved for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). In addition, we have signed an exclusive license agreement with Eagle Pharmaceuticals for TREAKISYM liquid formulations (RTD formulation and RI administration) in Japan. Regarding TREAKISYM, we are actively engaged in joint research with Kyoto University and exploring new development possibilities.
What is non-Hodgkin's lymphoma?
Malignant lymphoma is a malignant tumor in which lymphocytes in white blood cells have become cancerous, and is a disease in which swollen lymph nodes and masses form. It is divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma, and the majority of Japanese malignant lymphomas are non-Hodgkin's lymphoma.
Antibody therapy is administered with rituximab as the first-line drug for this disease, but currently there is no established treatment for cases of ineffectiveness or recurrence.
Related Sites
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
Journal of Clinical Oncology (JCO)
NCCN Guldelines
* User registration (free) is required to view information.